查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790381

腫瘤分子診斷市場規模、佔有率和趨勢分析報告：按類型、產品、技術、地區和細分市場預測，2025 年至 2033 年

Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 136 Pages | 商品交期: 2-10個工作天內

價格

腫瘤分子診斷市場概況

2024 年全球腫瘤分子診斷市場規模估計為 37.5 億美元，預計到 2030 年將達到 63.5 億美元，2025 年至 2033 年期間的複合年成長率為 5.5%。該市場透過分子技術識別基因突變、基因表現模式和腫瘤特異性生物標記物，支持各種癌症的檢測、預後和監測。

成長的動力源自於全球癌症發生率的上升、精準醫療的日益普及以及 PCR、NGS 和液態切片平台等診斷技術的持續創新。

此外，對早期癌症檢測和個人化治療策略的日益成長的需求正在促進整個醫療保健系統的市場擴張。

基於腫瘤的分子診斷透過分析DNA、RNA或蛋白質來檢測與癌症相關的基因變異，並指導臨床決策。這些檢測有助於識別與各種癌症相關的特定突變、基因表現和生物標記物，從而實現更準確的診斷、預後和治療方案選擇。這些檢測通常用於檢測乳癌、肺癌、結腸癌和攝護腺癌。

這些診斷技術在個人化醫療中發揮關鍵作用，它能為患者配對標靶治療並監測治療效果。其應用範圍涵蓋醫院實驗室、參考實驗室和研究機構。 PCR、新一代定序 (NGS) 和液態切片等技術的不斷進步，使這些檢測更有效率且方便。隨著癌症治療朝向個人化護理方向發展，分子診斷已成為癌症管理的重要組成部分。

目錄

第1章基於腫瘤的分子診斷市場：調查方法和範圍

2. 腫瘤分子診斷市場：執行摘要

  • 市場概述
  • 類型和產品簡介
  • 技術簡介
  • 競爭格局簡介

3. 基於腫瘤的分子診斷市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 全球癌症發生率上升
    • 精準醫療簡介
    • 分子檢測技術的進展
  • 市場限制因素分析
    • 測試和設備高成本
    • 報銷和法律規範不一致
    • 資源貧乏地區的交通受限
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章基於腫瘤的分子診斷市場類型、估計和趨勢分析

  • 基於腫瘤的分子診斷市場：類型變異分析
  • 乳癌
  • 攝護腺癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 血癌
  • 腎癌
  • 其他

第5章腫瘤分子診斷市場產品、預測與趨勢分析

  • 基於腫瘤的分子診斷市場：產品變異分析
  • 裝置
  • 試劑
  • 其他

6. 腫瘤分子診斷市場（依技術、估值和趨勢分析）

  • 基於腫瘤的分子診斷市場：技術波動分析
  • PCR
  • 原位雜合反應
  • 惰性
  • 晶片和微陣列
  • 質譜法
  • 順序
  • TMA
  • 其他

第7章 腫瘤分子診斷市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 新品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市場佔有率分析（2024年）
  • 公司熱圖分析
  • 公司簡介
    • Abbott
    • Bayer AG
    • BD
    • Cepheid
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic, Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens
    • Sysmex
Product Code: 978-1-68038-699-8

Oncology Based Molecular Diagnostics Market Summary

The global oncology based molecular diagnostics market size was estimated at USD 3.75 billion in 2024 and is projected to reach USD 6.35 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2033. This market supports the detection, prognosis, and monitoring of various cancers by identifying genetic mutations, gene expression patterns, and tumor-specific biomarkers through molecular techniques.

Growth is driven by the increasing global cancer burden, growing adoption of precision medicine, and continued innovation in diagnostic technologies such as PCR, NGS, and liquid biopsy platforms.

In addition, rising demand for early cancer detection and personalized therapeutic strategies contributes to market expansion across healthcare systems.

Oncology-based molecular diagnostics involve analyzing DNA, RNA, or proteins to detect cancer-related genetic alterations and guide clinical decisions. These tests help identify specific mutations, gene expressions, or biomarkers associated with various cancers, allowing for more accurate diagnosis, prognosis, and treatment selection. They are commonly used to detect breast, lung, colorectal, and prostate cancers.

These diagnostics play a key role in personalized medicine by helping match patients with targeted therapies and monitoring treatment response. Applications span across hospital labs, reference labs, and research institutions. With continuous improvements in technologies like PCR, next-generation sequencing (NGS), and liquid biopsy, these tests are becoming more efficient and accessible. With oncology care shifting toward individualized treatment, molecular diagnostics have become a critical component of cancer management.

Global Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology based molecular diagnostics market report based on product, technology, type, and region:

  • Type Outlook (Revenue, USD Million; 2021 - 2033)
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Others
  • Product Outlook (Revenue, USD Million; 2021 - 2033)
  • Instruments
  • Reagents
  • Others
  • Technology Outlook (Revenue, USD Million; 2021 - 2033)
  • PCR
  • In situ hybridization
  • INAAT
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • TMA
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

ac

Table of Contents

Chapter 1. Oncology Based Molecular Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Product Segment
      • 1.1.1.3. Technology segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Oncology Based Molecular Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Technology Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Global Cancer Prevalence
    • 3.4.2. Adoption of Precision Medicine
    • 3.4.3. Advances in Molecular Testing Technologies
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Costs of Testing and Equipment
    • 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
    • 3.5.3. Limited Access in Low-Resource Regions
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
  • 4.2. Breast Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Prostate Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Colorectal Cancer
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Cervical Cancer
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Liver Cancer
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Lung Cancer
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Blood Cancer
    • 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Kidney Cancer
    • 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

  • 5.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.3. Reagents
    • 5.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4. Others
    • 5.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • 6.2. PCR
    • 6.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3. In situ hybridization
    • 6.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4. INAAT
    • 6.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Chips and microarrays
    • 6.5.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Mass spectrometry
    • 6.6.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. TMA
    • 6.8.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oncology Based Molecular Diagnostics Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Oncology Based Molecular Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Type Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Abbott
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bayer AG
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. BD
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cepheid
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Agilent Technologies, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Danaher
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Hologic, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Qiagen
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Type Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Siemens
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Type Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sysmex
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Type Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table. 1. List Of Secondary Sources
  • Table. 2. List Of Abbreviation
  • Table. 3. Global Oncology Based Molecular Diagnostics Market, By Region, 2021 - 2030 (USD Million)
  • Table. 4. Global Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 5. Global Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 6. Global Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 7. North America Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 8. North America Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 9. North America Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 10. North America Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 11. U.S. Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 12. U.S. Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 13. U.S. Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 14. Canada Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 15. Canada Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 16. Canada Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 17. Mexico Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 18. Mexico Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 19. Mexico Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 20. Europe Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 21. Europe Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 22. Europe Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 23. Europe Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 24. UK Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 25. UK Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 26. UK Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 27. Germany Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 28. Germany Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 29. Germany Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 30. France Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 31. France Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 32. France Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 33. Italy Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 34. Italy Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 35. Italy Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 36. Spain Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 37. Spain Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 38. Spain Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 39. Sweden Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 40. Sweden Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 41. Sweden Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 42. Norway Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 43. Norway Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 44. Norway Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 45. Denmark Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 46. Denmark Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 47. Denmark Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 48. Asia Pacific Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 49. Asia Pacific Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 50. Asia Pacific Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 51. Asia Pacific Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 52. Japan Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 53. Japan Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 54. Japan Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 55. China Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 56. China Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 57. China Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 58. India Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 59. India Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 60. India Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 61. Australia Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 62. Australia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 63. Australia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 64. Thailand Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 65. Thailand Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 66. Thailand Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 67. South Korea Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 68. South Korea Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 69. South Korea Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 70. Latin America Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 71. Latin America Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 72. Latin America Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 73. Latin America Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 74. Brazil Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 75. Brazil Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 76. Brazil Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 77. Argentina Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 78. Argentina Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 79. Argentina Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 80. MEA Oncology Based Molecular Diagnostics Market, By Country, 2021 - 2030 (USD Million)
  • Table. 81. MEA Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 82. MEA Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 83. MEA Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 84. South Africa Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 85. South Africa Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 86. South Africa Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 87. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 88. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 89. Saudi Arabia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 90. UAE Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD Million)
  • Table. 91. UAE Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 92. UAE Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)
  • Table. 93. Kuwait Oncology Based Molecular Diagnostics Market, By Technology, 2021 - 2030 (USD)
  • Table. 94. Kuwait Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2030 (USD Million)
  • Table. 95. Kuwait Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Market Summary
  • Fig. 4 Market Segmentation & Scope
  • Fig. 5 Market Size and Growth Prospects
  • Fig. 6 Global Oncology Based Molecular Diagnostics Market- Key Market Driver Analysis
  • Fig. 7 Global Oncology Based Molecular Diagnostics Market - Key Market Restraint Analysis
  • Fig. 8 Penetration & Growth Prospect Mapping
  • Fig. 9 Global Oncology Based Molecular Diagnostics Market - Porter's Analysis
  • Fig. 10 Global Oncology Based Molecular Diagnostics Market - PESTEL Analysis
  • Fig. 11 Global Oncology Based Molecular Diagnostics Market Type Outlook Key Takeaways
  • Fig. 12 Global Oncology Based Molecular Diagnostics Market: Type Movement Analysis
  • Fig. 13 Breast Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Prostate Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Colorectal Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Cervical Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Liver Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Lung Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Blood Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Kidney Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Others Cancer Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Oncology Based Molecular Diagnostics Market Product Outlook Key Takeaways
  • Fig. 23 Global Oncology Based Molecular Diagnostics Market: Product Movement Analysis
  • Fig. 24 Instruments Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Reagents Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Global Oncology Based Molecular Diagnostics Market Technology Outlook Key Takeaways
  • Fig. 28 Global Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
  • Fig. 29 PCR Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 30 In Situ Hybridization Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 31 INAAT Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Chips and Microarrays Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Mass Spectrometry Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Sequencing Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 35 TMA Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Regional Marketplace: Key Takeaways
  • Fig. 38 Global Oncology Based Molecular Diagnostics Market: Regional Movement Analysis
  • Fig. 39 North America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 US Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 61 Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 62 MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 63 South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 64 Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 65 UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 66 Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 67 Strategy Framework